Copyright
©The Author(s) 2016.
World J Gastroenterol. Oct 28, 2016; 22(40): 8967-8977
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Published online Oct 28, 2016. doi: 10.3748/wjg.v22.i40.8967
Figure 2 Antitumor effects of deferasirox in hepatoma cell lines.
A: Deferasirox (DFX) exhibited antiproliferative effects against each cell line in a dose-dependent manner as revealed by MTT assay. Bars represent SD; B: Colorimetric assay of caspase-3 activity showing activation of caspase-3 by DFX in a dose-dependent manner. Bars represent SD.
- Citation: Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977
- URL: https://www.wjgnet.com/1007-9327/full/v22/i40/8967.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i40.8967